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The stable accumulation of p53 is detrimental to the cell because it blocks cell growth and division.
Therefore, increases in p53 levels are tightly regulated, mainly by its transcriptional target, mdm2, that
downregulates p53. Elucidation of new signaling pathways requires the characterization of the members and
the nature of their connection. Vaccinia-related kinase 1 (VRK1) contributes to p53 stabilization by partly
interfering with its mdm2-mediated degradation, among other mechanisms; therefore, it is likely that some
form of autoregulation between VRK1 and p53 must occur. We report here the identification of an autoreg-
ulatory loop between p53 and its stabilizing VRK1. There is an inverse correlation between VRK1 and p53
levels in cell lines, and induction of p53 by UV light downregulates VRK1 in fibroblasts. As the amount of p53
protein increases, there is a downregulation of the VRK1 protein level independent of its promoter. This effect
is indirect but requires a transcriptionally active p53. The three most common transcriptionally inactive
mutations detected in hereditary (Li-Fraumeni syndrome) and sporadic human cancer, p53(R175H),
p53(R248W), and p53(R273H), as well as p53(R280K), are unable to induce downregulation of VRK1 protein.
The p53 isoforms 40p53 and p53, lacking the transactivation and oligomerization domains, respectively, do
not downregulate VRK1. VRK1 downregulation induced by p53 is independent of mdm2 activity and protea-
some-mediated degradation since it occurs in the presence of proteasome inhibitors and in mdm2-deficient
cells. The degradation of VRK1 is sensitive to chloroquine, an inhibitor of the late endosome-lysosome
transport, and to serine protease inhibitors of the lysosomal pathway.
The accumulation of the tumor suppressor protein p53 oc-
curs in response to many different types of cellular stress or
DNA damage. The levels of p53 in response to stress present
a transient accumulation that may last a few hours (46). This
transient p53 accumulation induces a variety of responses de-
signed to protect the cell and allow for damage repair by
stopping the cell cycle (1, 28, 38, 43, 57, 61) or inducing apop-
tosis (41, 52, 62). If the level of p53 is maintained at a high level
when unnecessary, there would be a permanent block to cell
cycle progression or the cells will die. In any case, the stable
and prolonged accumulation of p53 is incompatible with life.
Therefore, the p53 molecule has evolved in a way that it is
always present at low levels, and when it is stabilized, the
accumulation occurs in a transient manner. The normal p53
levels are tightly regulated, and mechanisms aiming at its
downregulation are highly developed. This is achieved in part
by having a short half-life of about 20 min and, in case of an
increase in p53 levels, by the induction of negative regulatory
proteins for p53. The best-characterized mechanism is p53
downregulation by one of its transcriptional targets, hdm2/
mdm2 (34), so that the induction of mdm2 leads to p53 ubiq-
uitination and degradation by the proteasome (32, 53). The
p53 protein is held at low levels under normal growth condi-
tions, and upon stress its level increases rapidly (41) with the
subsequent transcriptional activation, including that of hdm2.
Hdm2 is a ubiquitin ligase that promotes downregulation of
p53, bringing its levels down to basal ones. Therefore, it can be
considered that there are waves of p53 accumulation whose
magnitude may vary depending on the type of stimulation or
the cell type (24). The sequential expression of p53 and mdm2
might also contribute to oscillations in their levels (27). The
same occurs with other p53 negative regulators that are also
transcriptional targets, as is the case for other ubiquitin ligases
such as COP1 (11). The downregulation of positive modulators
by p53, such as chk1, has been also reported (15). The p53
mutant (R273H), present in sporadic cancers and in Li-Frau-
meni syndrome patients, accumulates in human tumors and
has its properties altered with oncogenic potential (25, 39).
The p53 mutants detected in many tumors are likely to have
altered these autoregulatory mechanisms, but these alterations
have not been characterized. Recently, it has been shown that
variant p53 proteins lacking either the transactivation (11) or
the oligomerization domains (11) but retaining their ability to
activate gene transcription can be generated by alternative
splicing (8); these variant p53 proteins may have modifications
in their regulatory mechanisms.
The human vaccinia-related kinase 1 (VRK1) (26), a mem-
ber of a new Ser-Thr kinase family in the human kinome (30)
has autophosphorylation activity (29, 36) and also phosphoryl-
ates different transcription factors such as p53 (4, 29, 58, 23),
c-Jun (50), ATF2 (51), and nuclear factor BAF (37). VRK1 is
able to induce p53 stabilization by a complex mechanism, a
component of which is the phosphorylation of p53 in Thr18 (4,
29), partly preventing its interaction with mdm2 and promoting
p300 recruitment that leads to p53 accumulation and transcrip-
tional activation (58). p53 stabilization by VRK1 has been
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postulated to be a basic control process that operates in cells
under normal growth conditions in the absence of or under
suboptimal stress and that permits p53 to remain in a readiness
state or operate in minor damage responses, such as during
replication (58). VRK1 appears to be necessary for a basic
control mechanism in cell proliferation since its loss, induced
by small interfering RNA (siRNA) and in the absence of stress
stimulation, leads to a retardation of cell division and cell
death by a mechanism not yet identified (58). In human head
and neck squamous cell carcinomas, VRK1 correlates with
established proliferation markers, which suggests that VRK1
might be playing a role early in the G1 phase of the cell cycle
(47).
We hypothesized that some cross-regulation between VRK1
and p53 proteins must exist so that p53 stabilization can be
reversed; this mechanism should involve the inactivation in
some way of VRK1 so that its loss will permit the downregu-
lation of p53 by mdm2 or any other mechanism. Elucidation of
signaling networks implies the identification of interacting
molecules and the characterization of their interaction in order
to identify their contribution to different types of biological
effects (42). In this report we have identified that the accumu-
lation of p53 is able to induce the downregulation of its stabi-
lizing protein, VRK1, and this process requires the contribu-
tion of different p53 domains, does not involve VRK1
transcriptional regulation, and is mediated by the lysosomal
pathway of protein degradation.
MATERIALS AND METHODS
Plasmids, antibodies, and reagents. The VRK1 constructs, pCEFL-HA-
VRK1, pCEFL-HA-VRK1(K179E), and pCDNA3.1-VRK1-myc coding either
for the wild-type VRK1 or the VRK1(K179E) inactive mutant have been previ-
ously described (58). The plasmid pCB6p53, containing human p53 wild-type
cDNA, plasmid pCB6p53T18D (2), and plasmid pCOC-Mdm2-X2 coding for
the Mdm2 protein were from K. Vousden (The Beatson Institute, Glasgow,
United Kingdom); the transcriptionally defective mutant p53(R280K) was from
A. J. Levine (Rockefeller University, New York) (12); the mutant plasmids
pCMV-p53(R175H), pCMV-p53(R248W), and pCMV-p53(R273H) were from
Bert Vogelstein (Johns Hopkins University, Baltimore, MD); plasmid pCMV-
p53(L22Q, W23S) was from K. Roemer (7); plasmids expressing the p53 iso-
forms p53 and 40p53 (p47) were from J.C. Bourdon (Dundee University,
Scotland) (8); and pCMW-p53(L322A) and pCDNA3-p53C60 were from S.
Camus (Institute of Molecular and Cellular Biology, Singapore). The plasmid
BRR12-ubiquitin-His (pUbiquitin-His) was from S. Lain and D. Lane (Dundee
University, Scotland). The p53 siRNA expression plasmid pSUPER.retro.p53
(Oligoengine, Seattle, WA) was used where indicated to suppress the expression
of p53. All plasmids used for transfection were endotoxin free and purified with
a JetStar Maxi kit from Genomed (Bad Oeynhausen, Germany).
The anti--actin antibody was from Sigma (St. Louis, MO). The hemagglutinin
(HA) tag was detected with a mouse monoclonal antibody HA-probe (F7) from
Covance (Berkeley, Calif.). The p53 protein was detected with a mixture of DO1
antibody (Santa Cruz, CA) and Pab1801 (Santa Cruz, CA) used at 1:500 and
1:1,000, respectively. The p53 isoform, 40p53 (p47), lacking the transactivation
domain was detected with the CM1 polyclonal antibody at a dilution of 1:20,000
(from A. Craig, Dundee University, Scotland). VRK1 was detected using a rabbit
polyclonal antibody (VE1) or a mouse monoclonal antibody (1F6 clone) made
against a VRK1 fusion protein. Poly(ADP-ribose) polymerase was determined
with a monoclonal antibody from Enzyme Systems Products (Livermore, CA).
As secondary antibodies, a goat anti-mouse-horseradish peroxidase or a goat
anti-rabbit-horseradish peroxidase (Amersham Pharmacia Biotech) was used at
1:5,000 in Western blotting.
The following protease inhibitors were used: pepstatin for aspartyl proteases;
phenylmethylsulfonyl fluoride (PMSF), aprotinin, diisopropylfluorophosphate
(DFP), soybean trypsin inhibitor (STI), and leupeptin for serine proteases;
iodoacetic acid (IAA) and leupeptin for cysteine proteases; EDTA and 1,10-
phenantroline for metaloproteasas; and ALLN, calpain inhibitor III, calpeptin,
EST, and PD150606 for calpain proteases (all from Sigma). Chloroquine was
from Sigma.
Cell lines and transfections. The human lung cancer cell line H1299 (p53/)
was grown in RPMI medium supplemented with 10% fetal calf serum, glutamine,
penicillin, and streptomycin in a humidified atmosphere and 5% CO2. HeLa
cells, U2OS (p16/), and the WS1 normal human fibroblast cell line (ATCC
CRL-1502) were grown in Dulbecco’s modified Eagle’s medium with the same
supplements. For transfection experiments, H1299 cells were plated in 60- or
100-mm dishes and transfected with the plasmid indicated in the specific exper-
iments either by the calcium phosphate precipitation method or with JetPI
reagent following the manufacturer’s instructions (Polytransfection; Illkirch,
France). Unless otherwise indicated, the cells were lysed 36 h posttransfection in
lysis buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 5 mM EDTA, and 1%Triton
X-100, plus protease and phosphatase inhibitors), and 40 g of whole-cell extract
was processed for sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis and subjected to immunoblotting with the indicated antibodies. The
immortalized fibroblasts from double knockout p53/Mdm2 mice (p53/,
mdm2/) were a gift of G. Lozano (MD Anderson Cancer Center, Houston,
TX) and were grown in Dulbecco’s modified Eagle’s medium with 10% fetal calf
serum and antibiotics. Where indicated, the proteasome inhibitor MG132 (Cal-
biochem) was used at 50 M for 6 h. Tetracycline was from Sigma (St. Louis,
MO) and was used at a concentration of 2 g/ml. Stimulation of the cells with
UV light was done in a Stratalinker from Stratagene (San Diego, CA).
Immunoblotting. Total protein extracts were quantified using a Bio-Rad pro-
tein assay kit. Protein was fractionated in an SDS-polyacrylamide gel and trans-
ferred to a polyvinylidene difluoride Immobilon-P membrane (Millipore). The
membrane was blocked with TBS-T buffer (25 mM Tris, 50 mM NaCl, 2.5 mM
KCl, 0.1% Tween-20) and 5% nonfat milk. Afterwards the membrane was rinsed
with TBS-T buffer; and the specific primary antibody (indicated in individual
experiments) was added, and the membrane was incubated for 90 min at room
temperature. The membrane was rinsed and incubated with a secondary anti-
body conjugated with peroxidase for 30 min. The membrane was develop for
chemiluminescence with ECL reagent (Amersham) and exposed to X-ray films.
Quantification was always performed in the linear response range.
Quantitative RT-PCR. Reverse transcription-PCR (RT-PCR) was performed
as previously described (58). Briefly, H1299 cells were cotransfected as described
above with the plasmids indicated in the experiment, and total RNA was ex-
tracted using an RNAeasy extraction kit from QIAGEN (Hilden, Germany).
One hundred nanograms of total RNA was used in a one-step reverse transcrip-
tion real-time PCR amplification reaction using a Quantitec SYBR Green RT-
PCR kit from QIAGEN in an iCycler (Bio-Rad, Hercules, CA). The reaction was
analyzed with iCycler software (Bio-Rad). The primers used for VRK1 amplifi-
cation detection were 5-CCAACGAGCTGCAAAACCA-3 and 5-TGTCATG
TAGACCAGACCCCC-3; for GAPDH amplification detection, the primers
were 5-GGTCTTACTCCTTGGAGGCCATGT-3 and 5-ACCTAACTACAT
GGTTTACATGTT-3.
RESULTS
The level of VRK1 inversely correlates with p53 levels in cell
lines. During the course of the work, it was noticed that when
a cell had p53 wild-type protein, the level of transfected VRK1
detected was always lower than if the cell line lacked p53. Once
it was clear that this effect was not due to transfection effi-
ciency, the correlation with the cell genotype was intriguing
and suggested that the explanation might be related to the
connection of the two proteins in the pathway (58), with an
inverse relation between them. To determine if that might be
the case, the level of the two endogenous proteins, VRK1 and
p53, was determined in several cell lines (Fig. 1A). The cell
lines with wild-type p53 had lower levels of endogenous VRK1.
But in the two cell lines lacking p53, such as H1299 or HCT116
(p53 knockout), higher levels of endogenous VRK1 were
clearly detected (Fig. 1A). One of the effects of an active
VRK1 is to stabilize p53 by increasing its intracellular levels
(58), and a stable accumulation of p53 is known to be detri-
mental to the cell since it prevents cell division and might even
trigger an apoptotic response (3, 9, 43). Therefore, we consid-
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ered the possibility that higher levels of p53 might promote a
downregulation of its activator-stabilizer VRK1 protein, thus
forming an autoregulatory loop between p53 and VRK1, which
might be conceptually similar to the autoregulation between
Chk1 and p53 (15) or to the p53-mdm2 autoregulatory loop
(34). That interpretation might account for the different levels
of VRK1 observed, depending on the p53 genotype of cell
lines.
p53 accumulation induced by UV downregulates VRK1. To
determine if the level of p53 might indeed have an inverse
correlation with the level of VRK1, we studied the variation in
levels of both proteins in the cell response to stimulation with
UV irradiation. Human diploid fibroblasts, the WS1 cell line
(p53/), were treated with two doses of UV light, at 20 J/m2
or 40 J/m2, and cell extracts were analyzed by Western blotting
8 h after irradiation. In both cases the endogenous p53 was
stabilized, and there was a reduction of VRK1 levels (Fig. 1B).
Next, a time course of the response of WS1 cells irradiated
with 20 J/m2 was performed for a period of 24 h. As expected,
after UV treatment there was the expected fast stabilization of
p53 as a consequence of phosphorylation (46), but the accu-
mulation of p53 continued to increase, reaching significantly
much higher levels after 10 h (Fig. 1C), a response typical of
fibroblasts (16). After irradiation there was also a transient
increase in the level of VRK1 that reached a peak at 4 h, after
which it fell even below the initial level. The timing of this
reduction in VRK1 levels coincided with the time necessary for
p53-dependent de novo gene expression and with the increased
level of p53, suggesting that perhaps the accumulated p53
might be implicated in inducing the VRK1 downregulation.
Next, we tried to determine if this down-regulatory effect could
be reproduced by transfection of p53. To this end, the WS1
FIG. 1. Expression of endogenous p53 and VRK1 in tumor cell lines and in UV treated fibroblasts. (A) Expression of VRK1 and p53 in cell
lines that were p53 wild type (A549, U2OS, and WS1) or p53/ (H1299 or HCT116-p53 knockout). VRK1 and p53 were determined by Western
blotting, using actin as internal control. (B) Levels of p53 and VRK1 in human fibroblasts treated with the indicated dose of UV light; the extracts
were prepared 8 h after treatment and analyzed by Western blotting. (C) The levels of endogenous p53 and VRK1 in WS1 fibroblasts were detected
at different times after treatment with 20 J/m2 UV light. The proteins were identified by Western blotting with the corresponding antibodies
indicated in the methods section. (D) Normal human fibroblasts, cell line WS1, were transfected with increasing amounts of pCB6p53 as
indicated and 5 g of pCEFL-HA-VRK1. Cell extracts were prepared 36 h after transfection. The proteins were detected with the corresponding
antibodies by Western blotting, and to the right is shown the quantification of the normalized values.
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fibroblast cell line was transfected with increasing amounts of
p53 (plasmid pCB6p53) and a fixed amount of VRK1 (plas-
mid pCEFL-HA-VRK1). As the amount of p53 increased, it
was accompanied by a reduction in the level of VRK1 protein
in these cells (Fig. 1D).
p53 downregulates VRK1 protein level. To reproduce this
down-regulatory effect in an independent system, a new exper-
iment was designed using a variant of the H1299 (p53/,
p53Tet inducible) cell line that contains a p53 gene that is induc-
ible by addition of tetracycline to the culture. This cell line has
a basal level of p53 expression and thus mimics a normal cell
situation. This cell line was transfected with a fixed amount of
pCEFL-HA-VRK1, p53 expression was induced by the addi-
tion of tetracycline, and the level of VRK1 was determined at
different time points. After induction with tetracycline, as the
level of p53 increased with time, it was accompanied by a
reduction in the level of the VRK1 protein detected with an
antibody against the HA epitope tag (Fig. 2A).
To confirm that VRK1 protein downregulation was depen-
dent on the accumulation of p53 protein, a time course exper-
iment for VRK1 expression alone or together with p53 over-
expression was performed (Fig. 2B). For this experiment,
H1299 (p53/) cells were transfected with plasmids pCEFL-
HA-VRK1 and pCB6p53, and at different time points cell
extracts were prepared and analyzed by immunoblotting. In
the absence of p53, VRK1 protein levels increased constantly,
as expected, given the high degree of VRK1 stability. However,
in the presence of p53, at first VRK1 increased as a result of de
novo protein synthesis; but when there was also a detectable
accumulation of p53, VRK1 accumulation slowed down and
finally came to a stop, which was particularly noticeable be-
tween 24 and 36 h after transfection (Fig. 2B). These data
suggested that the effect depends on the concentration of p53
in the cell and was probably due to the modification of gene
transcription as a consequence.
To further determine whether such an effect was occurring
in a p53 dose-dependent manner and was promoter indepen-
dent, an experiment was designed to reproduce the previous
inducible effect by transfection using the H1299 cell line (p53/).
This cell line was transfected with increasing amounts of
pCB6p53 and a fixed amount of pCEFL-HA-VRK1 (Fig.
2C), which express VRK1 from a Moloney murine leukemia
virus promoter; with pCDNA3.1-VRK1-myc, which expresses
VRK1 from a cytomegalovirus promoter; or with pEF1-VRK1,
which uses the EF1 gene promoter. In this experiment it was
observed that the higher the level of p53, the lower the amount
of VRK1 protein detected in cell extracts (Fig. 2C). The effect
of p53 on VRK1 was similar independent of the type of pro-
moter from which VRK1 was expressed (not shown). The
effect was also confirmed in other tumor cell lines, such as
HT144, WS1, A549, and in U2OS (p16/), suggesting that the
effect is independent of cell type and that p16 is not involved in
this process (not shown). These results indicate that the effect
is more general and does not depend on the genetic peculiar-
ities of the particular tumor cell line or promoter used.
Contribution of p53 domains to VRK1 protein downregula-
tion. To determine the requirements of the p53 protein re-
quired to induce the downregulation of VRK1, the contribu-
tions of three main p53 functional regions, the transactivation,
DNA binding, and oligomerization domains, were analyzed.
The potential contribution of the N-terminal transactivation
domain of p53 was studied using three different types of mu-
tants: a phosphorylation mutant that mimics phosphorylation
in threonine-18, p53(T18D), the p53(L22Q, W23S) conforma-
tional mutant than retains its transcriptional activation role but
has different effects on double-strand DNA repair and apop-
tosis (7, 31), and the isoform 40p53, known as p47, that lacks
the first 40 amino acids of the transactivation domain (8). This
isoform functions as a dominant negative of p53 growth sup-
pression properties (10, 14). The phosphorylation and the con-
formational mutants were able to induce the downregulation
of VRK1 in a dose-dependent manner; however, the 40p53,
lacking the first forty amino acids, has lost this role (Fig. 3A).
These results indicate that the first 40 residues of the transac-
tivation domain are required for this effect and reflect a func-
tional difference in p53 isoforms. Different N-terminal phos-
phorylation mutants were also assayed with same results as
with the p53(T18D) (not shown). p53 interaction with many
regulators is mediated by the N-terminal transactivation do-
main, and it is possible that such interaction is necessary for
p53-mediated VRK1 downregulation.
To ascertain if the DNA binding domain of p53 was a re-
quirement for induction of VRK1 downregulation, several mu-
tants in this domain were studied. The three most common
naturally occurring p53 mutants in human cancer, both spo-
radic and hereditary, were studied. The conformational mutant
p53(R175H) and the DNA contact mutants p53(R248W)
and p53(R273H) (55) account for approximately one-third of
all p53 mutations in human cancer (6, 56). A p53 mutant
[p53(R280K)] engineered to prevent binding to DNA and
without effects on other p53 properties was also studied (12).
All of these p53 mutants were unable to induce a downregu-
lation of VRK1 protein levels (Fig. 3B). This lack of effect
indicated that the action of p53 on VRK1 levels requires the
integrity of the DNA binding domain and is therefore probably
mediated by a DNA-bound form of p53. This result opens the
possibility of the effect being mediated by a p53-dependent
induction or repression of a gene not yet identified.
Finally, the potential contribution of the p53 oligomeriza-
tion domain was analyzed. The C terminus is necessary for
the anti-growth arrest and anti-apoptotic effects of p53 (54).
Three different p53 variants in this domain were used: the
p53(L332A) conformational mutant that has a defective oli-
gomerization, pCDNA3-p53C60 (lacking the last 60 resi-
dues), and the p53 isoform lacking the oligomerization do-
main (8). The loss of this domain resulted in the loss of the
effect on VRK1, while the conformational mutant p53(L332A)
was slightly less efficient in inducing it (Fig. 3C). These data
suggested that oligomerization of p53 is necessary for the in-
duction of VRK1 protein downregulation and also indicated a
functional difference between p53 isoforms. This further sup-
ports the idea of a transcriptionally active p53 role in VRK1
downregulation.
p53 does not affect VRK1 transcription. There is the possi-
bility that p53 might affect the expression of the VRK1 gene
and contribute in that way to VRK1 regulation. However, the
previous observations in which the effect was detected by ex-
pressing VRK1 from different promoters do not support this
possibility. To further rule out this possibility, mRNA levels
were determined by quantitative RT-PCR under conditions
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FIG. 2. Downregulation of VRK1 by increasing levels of p53. (A) Inducible endogenous p53 downregulated VRK1. H1299 cells (p53Tet inducible) were
transfected with 5g of pCEFL-HA-VRK1, and the p53 gene was induced with tetracycline. As the level of p53 increased, there was a noticeable decrease
of VRK1 expression levels. Cell extracts were prepared at different time points after induction, and the proteins were detected by immunoblot analysis
with the quantification shown in the graph to the right. (B) Time course of p53 and VRK1 protein levels. H1299 cells were transfected with
pCEFL-HA-VRK1 (4 g) with and without pCB6p53 (200 ng). At different hours after transfection, cell extracts were prepared and analyzed by
Western blotting for the amount of each protein. The quantification of the blots is shown in the graph to illustrate the trend in protein levels. The
accumulation of p53 interferes with the accumulation of VRK1. The proteins were detected with the corresponding antibodies by Western blotting, and
to the right is shown the quantification of the normalized values. (C) H1299 cells (p53/) were transfected with a fixed amount (5 g) of pCEFL-HA-
VRK1 and increasing amounts of p53 (wild type) to detect the effect of increasing p53 on VRK1 expressed from different promoters.
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where p53 was overexpressed by transfection with three differ-
ent amounts (0.2, 0.4, and 0.8 g) of plasmid pCB6p53. A
similar result was obtained with the three doses of p53, and
results of the latter two are shown in Fig. 4. These concentra-
tions of p53 induced a strong downregulation of VRK1 protein
levels as shown by immunoblot analysis (Fig. 4A); therefore, at
these points or earlier, there should also be a decrease in
VRK1 RNA if this effect is mediated by downregulation of the
promoter. The level of p53 protein did not appear to have an
effect on VRK1 transcription (Fig. 4B), since the levels of
VRK1 mRNA, both endogenous and transfected, were not
significantly affected by p53, as shown by the start of amplifi-
cation at the same cycle in both samples (indicated by an arrow
in the figure) at a time when there is already an important
reduction in VRK1 protein level. This effect was observed even
when both proteins were expressed from the same cytomega-
lovirus promoter; therefore, the mechanism cannot be due to a
p53 effect on the type of promoter used to express VRK1.
FIG. 3. Implication of p53 protein domains in the induction of VRK1 downregulation. (A) Role of the transactivation domain. The effects of
the phosphorylation mimicking mutant p53(T18D), the conformational double mutant p53(L22Q, W23S), and the p53 isoform lacking the
transactivation domain (40p53) were tested in combination with pCEFL-HA-VRK1 (5 g). The 40p53 isoform was detected with the CM1
polyclonal antibody. At the bottom is shown the quantification of the blots to illustrate the changes in both proteins. (B) Contribution of the p53
DNA binding domain. Lack of effect of the most common p53 transcriptional mutants, p53(R175H), p53(R248W), and p53(R273H) on the level
of VRK1 protein expressed from plasmid pCEFL-HA-VRK1 (5 g). Cell extracts were prepared 36 h after transfection, and the levels of both
proteins were determined by Western blotting. The transfected VRK1 was detected with an antibody specific for the HA epitope. (C) Contribution
of the p53 oligomerization domain. The conformational mutant p53(L322A) and isoforms lacking the C-terminal region p53 and p53C60 were
studied.
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VRK1 downregulation induced by p53 protein is abrogated
by p53 siRNA. To further establish the dependence of VRK1
downregulation on p53 levels, a different approach was used
based on the use of siRNA. For this experiment a fixed level of
p53 protein expression was selected, the one corresponding to
200 ng of pCB6p53, and this p53 protein was eliminated with
vector-delivered short hairpin RNA (shRNA) specific for p53
(plasmid pSUPER.retro.p53). The p53 protein was effectively
eliminated, and in this situation the level of VRK1 was near its
control level (Fig. 5A, top). The p53 shRNA does not affect
VRK1 (Fig. 5A, bottom). Next, to show the dependence on
p53 levels an experiment was designed in such a way that p53
was first increased in a concentration-dependent manner, and
at the high point, it was reduced by shRNA also in a concen-
tration-dependent way. In this experiment the levels of p53 and
VRK1 behave inversely, establishing that cycles of fluctuations
of these two proteins can occur based on the p53 protein
expression levels (Fig. 5B).
The downregulation of VRK1 by p53 is mediated by an
mdm2-independent mechanism. A likely mechanism by which
p53 is able to downregulate VRK1 might be the result of a
proteolytic activity that is activated, directly or indirectly, fol-
lowing the activation of p53-dependent transcription. In this
context the most likely mechanism by which VRK1 might be
downregulated as a consequence of p53 transcription is by the
action of a ubiquitin ligase, such as that encoded by mdm2/
hdm2, which represents the proteasome pathway of protein
degradation. Furthermore, the mdm2 gene is a p53 transcrip-
tional target, and this protein promotes p53 degradation, fol-
FIG. 4. The p53 protein does not affect VRK1 gene transcription
levels. (A) Levels of p53 and VRK1 protein at the time point used for
RNA determination. The levels of VRK1 protein in cells transfected
with either 0.4 or 0.8 g of plasmid pCB6p53 are shown. The extracts
were prepared 36 h after transfection. The proteins were detected by
immunoblotting. (B) The levels of VRK1 mRNA, whether after p53
overexpression or not, were determined by RT-PCR as described in
Materials and Methods. The results obtained in cells transfected with
0.4 (p53) and 0.8 (p53) g of plasmid pCB6p53 are shown.
FIG. 5. p53 siRNA blocks the downregulation of VRK1 in H1299
cells. (A) H1299 cells were transfected with pCB6p53 and an siRNA
specific for p53 (pSUPER.retro.p53) as well as pCEFL-HA-VRK1 (5
g) in different combinations to show that the level of the cotrans-
fected p53 expressed from plasmid pCB6p53 is downregulated. The
cell extracts were prepared 36 h after transfection and analyzed by
Western blotting with the corresponding antibodies. (B) H1299 cells
were transfected with pCB6p53 and 5 g of pCEFL-HA-VRK1. The
increase in p53 protein, as expected, downregulated the level of VRK1,
but when cells were cotransfected with increasing amounts of siRNA
specific for p53, expression plasmid pSUPER.retro.p53, the downregu-
lation of VRK1 was reduced. The graph shows the quantification of
results for both proteins.
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lowing ubiquitination, by the proteasome (35). Therefore, it
could be postulated that VRK1 could also be downregulated
by mdm2 or another ubiquitin ligase. To determine if mdm2
might be implicated in the downregulation of VRK1 by p53,
different experiments were performed. First, H1299 cells were
transfected with increasing amounts of plasmid pCOC-mdm2.
The increasing levels of Mdm2 protein by itself did not affect
the amount or migration in the SDS-polyacrylamide gel elec-
trophoresis gel of VRK1 protein detected in the cells by West-
ern blotting (FIG. 6A, top blots), indicating that it is not
ubiquitinated by Mdm2. As a control of the mdm2 ability to
induce the degradation of target proteins by ubiquitination,
H1299 cells were cotransfected in parallel with p53 in the
presence or absence of mdm2 to show that mdm2 did indeed
downregulate p53 in this cell line (Fig. 6A, bottom blots).
To confirm that VRK1 is not ubiquitinated, we performed
an experiment under conditions where protein ubiquitination
can be detected using p53 as a positive control. The H1299 cell
was transfected with pCOC-mdm2 and either pCB6p53 or
pCEFL-HA-VRK1 in the presence of pUbiquitin-His, so that
ubiquitin is not limiting, and of the proteasome inhibitor
MG132 to prevent degradation of the proteins by the protea-
some and permit accumulation of ubiquitinated proteins. The
change in migration of ubiquitinated p53 was clearly detected
in the form of a p53 ladder, but there was no change in the
migration in the gel of the VRK1 protein (Fig. 6B), suggesting
that ubiquitinated forms of this protein do not exist under
these conditions.
To further rule out any participation of mdm2, murine em-
bryo fibroblasts deficient in p53 and mdm2 derived from dou-
ble-knockout mice were used (35). These fibroblasts were
transfected with increasing amounts of pCB653 and a fixed
amount of pCEFL-HA-VRK1. The downregulation of VRK1
was also achieved (Fig. 6C) indicating that mdm2 was not
necessary for this effect. Next, to rule out the possibility that
the effect is not mediated by any other ubiquitin ligase and
degradation in the proteasome, a similar experiment was per-
formed in the presence of the proteasome inhibitor MG132.
The proteasome inhibitor was able to maintain even higher
levels of p53 (Fig. 6C), indicating that even in the absence of
mdm2 there was some proteasome-mediated degradation of
p53; but the effect of p53 levels on VRK1 was always observed,
and its magnitude was even larger in the presence of MG132 as
the levels of p53 were higher (Fig. 6C), probably resulting from
blocking the effect of other ubiquitin-ligases. These experi-
ments suggested that the downregulation of VRK1 was medi-
ated by an mdm2- and proteasome-independent mechanism.
p53 degradation by mdm2 partially prevented the downregu-
lation of VRK1, not by a direct Mdm2 effect but as a conse-
quence of reduced p53 levels (not shown).
Downregulation of VRK1 is sensitive to inhibition of endo-
some-lysosome traffic and lysosomal protease inhibitors. The
alternative pathway of protein degradation is represented by
the lysosomal pathway, mainly composed of acidic serine and
cysteine proteases (17). In this pathway the proteins have to be
transported from late endosomes to the lysosomes, where they
are degraded by lysosomal serine proteases that function at an
acidic pH. Therefore, it was decided to test the potential im-
plication of this route by using a variety of endosome-lysosome
traffic and protease inhibitors that affect different types of
FIG. 6. Mdm2 is not implicated in p53 downregulation of VRK1.
(A) Mdm2 protein overexpression does not produce VRK1 degrada-
tion by itself. H1299 cells were transfected with 5 g of pCDNA-VRK1
expression plasmid alone or together with increasing amounts of plas-
mid encoding pCOC-Mdm2 where indicated. One microgram of plas-
mid (pUbiquitin-His) encoding ubiquitin was added in all cases. Also
0.2 g of pCB6p53 plasmid was cotransfected with Mdm2-encoding
plasmid under similar conditions (lower panel). Whole-cell extracts
were prepared 36 h after transfection and analyzed by Western blotting
with the corresponding antibody. (B) Detection of ubiquitination
in p53 but not VRK1 in H1299 cells. The cells were transfected
with plasmid pCOC-Mdm2 (4 g), pCEFL-HA-VRK1 (3 g), or
pCB6p53 (1 g) in the presence of 1 g of pUbiquitin-His. The cell
extracts were analyzed by immunoblotting with an anti-VRK1 antibody
or a mix of antibodies for p53 to detect their potential change in
migration in the gel if there was ubiquitination. (C) VRK1 downregu-
lation by p53 is independent of Mdm2 protein and proteasome-medi-
ated degradation. Mouse embryo fibroblasts derived from double
knockout mice (p53/ mdm2/) were cotransfected with the indi-
cated plasmids pCEFL-HA-VRK1 (3 g) or pCB6p53. Where indi-
cated, the proteasome inhibitor MG132 was added at 50 M. Cells
were processed as described in panel A, and levels of p53 and VRK1
proteins were detected.
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intracellular proteases. The movement of late endosomes to
lysosomes can be experimentally inhibited by chloroquine (18,
65). Therefore, the sensitivity of VRK1 downregulation to
inhibitors of the transport system was tested by performing a
dose-response analysis with chloroquine. As the amount of
chloroquine was increased in the range of 10 to 60 M, there
was an inhibition of p53-induced downregulation of VRK1
(Fig. 7A); at higher concentrations chloroquine was toxic to
the cells. These data indicated that VRK1 enters the late-
endosome to lysosome system, and thus, partial protection was
conferred by chloroquine.
Next, the sensitivity to a variety of protease inhibitors was
also determined. The protease inhibitors tested were pepstatin
for aspartyl proteases; PMSF, aprotinin, DFP, STI, and leu-
peptin for serine proteases; IAA and leupeptin for cysteine
proteases; EDTA and 1,10-phenantroline for metaloprotea-
sas; and ALLN, calpain inhibitor III, calpeptin, EST, and
PD150606 for calpain proteases. Because these inhibitors are
in general toxic, the cells 18 h after transfection were treated
for 5 h with the corresponding inhibitor, washed, and incu-
bated for an additional 5 h before the extracts were prepared.
Cells were lysed and analyzed by immunoblotting for the cor-
responding proteins (Fig. 7B). Most of the inhibitors of serine
proteases (aprotinin, leupeptin, and DFP) or cysteine pro-
teases such as leupeptin partially prevented the downregula-
tion of VRK1. Leupeptin is furthermore an established inhib-
itor of the lysosomal pathway of protein degradation (44).
None of the calpain inhibitors affected the downregulation
(not shown). The possible activation of caspases was also de-
termined by the analysis of poly(ADP-ribose) polymerase pro-
teolytic cleavage, which was not affected in these experiments,
suggesting that there was no activation of the caspase pathway
(not shown).
DISCUSSION
VRK1 is a nuclear kinase with p53 among its targets (29);
therefore, in this report we have attempted to characterize new
aspects of their interaction in the context of a novel signaling
pathway. This is particularly important since VRK1 is likely to
play an important role in the control of normal cell prolifera-
tion (58). Because VRK1 induces an accumulation of p53, it is
expected that the levels and activity of VRK1 will be tightly
regulated. Accumulation of p53 can have a deleterious effect
on the cell since it can stop cell division and induce apoptosis.
Once the biological effect of p53 has been achieved, it is rea-
sonable to expect that the stabilizing factor will return to basal
levels in some way; otherwise, there would be a permanent
activation and accumulation of p53. One of the mechanisms by
which VRK1 contributes to p53 stabilization is by phosphory-
lation of Thr18 that prevents the p53-Mdm2 interaction (19,
22, 48) and promotes p300 recruitment and transcriptional
activation (58). It was expected that a p53 stabilizing protein,
such as VRK1, should be the target of a down-regulatory
process. A downregulation of another p53 positive modulator,
the Chk1 protein, has already been identified (15). In this
report we have shown that increasing the level of intracellular
p53 led to the downregulation of VRK1 levels. The inverse
correlation between VRK1 and p53 observed in cell lines can
also be induced in vivo under conditions in which a stable
accumulation of p53 can be obtained, as is the case of stimu-
lation of fibroblasts with UV light that induces senescence
(60), but other ways to induce the effect more effectively may
be found. Senescence in fibroblasts is already known to be
accompanied by Thr18 phosphorylation and accumulation of
FIG. 7. VRK1 downregulation occurs in the lysosomal pathway.
(A) Sensitivity of VRK1 downregulation to the inhibition of the late
endosome to lysosome traffic by chloroquine. H1299 cells were trans-
fected with pCB6p53 and pCEFL-HA-VRK1. Chloroquine at the
indicated concentrations was added 12 h after transfection, and cell
extracts were prepared for immunoblot analysis 36 h after transfection.
(B) Effect of protease inhibitors on the downregulation of VRK1
induced by p53. H1299 cells were transfected with pCB6p53 and
pCEFL-HA-VRK1, and different protease inhibitors were added to
the culture 18 h after transfection. The inhibitors were used at the
specified concentrations for 5 h. The serine protease inhibitors were
the following: 1 mM PMSF, 10 l/ml aprotinin (Aprot), 0.1 mM DFP,
and 10 l/ml STI. The following protease inhibitors were also used: for
serine and cysteine, 50 M leupeptin (Leup); for cysteine, 50 M IAA;
and for aspartyl, 1 M pepstatin (Peps). As metalloprotease inhibitors,
5 mM EDTA and 5 mM 1,10-phenantroline (Phen) were used. Calpain
inhibitors were also tested with no effect. The cells were collected 23 h
after transfection and lysed for determination of VRK1 and p53 levels
by Western blotting. Ctr, controls without inhibitors.
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p53 (13). The inverse correlation can be reproduced by trans-
fection in different cell types, making it more amenable for its
characterization.
The contribution of p53 to VRK1 regulation is an interme-
diate step in the process for which it is absolutely essential, the
structural maintenance of p53 molecules, since alterations in
each domain affect the downregulation of VRK1. This require-
ment is important because it reflects a functional difference
between normal p53 and p53 mutated in human cancer, either
sporadic or hereditary, or p53 isoforms. The response is af-
fected by the transactivation domain of p53 since the effect is
lost in the case of 40p53, an isoform lacking the first 40 amino
acids, which have a dominant negative role and counteract
growth suppression (10, 14). However, the conformational mu-
tant p53(L22Q, W23S), which affects some response elements
but not others (7, 31, 45, 59), still induces downregulation.
Many p53 regulators interact with p53 through this N-terminal
domain. Therefore, it is likely that some p53 interaction not yet
identified could have a role in the VRK1 downregulation in-
duced by p53. The contribution of the integrity of the DNA-
binding domain is demonstrated by the loss of effect when
common mutations, either conformational or with loss of DNA
contact, are present. This might have consequences in tumors
bearing these mutations. Some conformational mutations are
not active and contribute to tumor development by routes
currently under characterization since their pattern of tumor
formation is different from that induced by structural mutants
affecting contact with DNA (25, 39). It is important to note
that this lack of effect occurs with the most common p53
mutations, detected in both sporadic tumors and hereditary
Li-Fraumeni syndrome (40). The dependence on the conser-
vation of the oligomerization domain is further consistent with
the requirement for the integrity of p53 as the formation of a
functional tetramer is also important for the effect. All these
data point to a potentially important functional consequence
for VRK1 downregulation since it does not occur when p53
isoforms lacking transactivation or oligomerization domains
are expressed (8, 10). The p53 gene is mutated in more than
half of human tumors (63), and the mutations are concentrated
in the DNA-binding domain affecting the transcriptional role
of p53. In tumors with p53 mutations, the mechanism respon-
sible for VRK1 negative regulation is probably not induced,
leading to a more stable VRK1 protein or even higher levels.
Since VRK1 activity is correlated with cell proliferation, these
tumor cell lines are likely to have a higher potential to divide,
but whether the process is successful will also depend on other
cell properties. The exact implication, if any, of this mechanism
in cancer progression has yet to be elucidated.
The results with the different p53 mutants indicate that the
mechanism appears to be either a direct consequence of a gene
regulated by p53 or an interaction of p53 with some regulator
that includes binding to DNA. The regulated phenomenon is
not the expression of VRK1 itself, since the effect is indepen-
dent of the type of promoter from which VRK1 was expressed,
either endogenous or from different types of plasmids. The
genes induced by p53 in the H1299 cell line have been partially
characterized by microarray analysis (20, 33, 49, 64), but a clear
candidate gene cannot be identified as a potential mediator of
the effect reported. VRK1 and other p53 activators act by
increasing p53 stability, with the consequent rise in p53 levels.
Several mechanisms ensure that p53 accumulation is transient,
and they include the transcriptional activation of negative
modulators, as is the case for mdm2, and the downregulation
of positive modulators, as is the case of VRK1, through the
transcription of other p53-dependent genes as an intermediate
step. It may be either a protease that can degrade VRK1 or a
protein that somehow modifies VRK1 stability, either by in-
teracting with it or by a covalent modification. Both may also
affect its kinase activity, which in some way can influence
VRK1 stability by making it more susceptible to enter the
proteolytic degradation via the lysosome. The inactive kinase
VRK1(K179E), although less stable, was also equally down-
regulated by p53 (unpublished results).
Intracellular proteins can be degraded by one of the two
alternative pathways, the proteasome or the lysosome. VRK1
lacks PEST sequences that would make a protein susceptible
to proteasome-mediated degradation (5, 21). Mechanistically,
the VRK1 downregulation induced by p53 is independent of a
proteasome-mediated pathway, and mdm2 is not implicated
since the downregulation was detected in mdm2-deficient cells
and was also insensitive to proteasome inhibitors. However,
the downregulation is sensitive to some serine protease inhib-
itors, suggesting that the final step is executed by a member this
protease family. In this group is included leupeptin, the pro-
totype inhibitor of the lysosome-mediated degradation path-
way (44). Therefore, it is highly likely that this is the pathway
responsible for the effect, but how VRK1 is targeted for deg-
radation is not known. This would be the step that requires
p53-dependent transcription to control the targeting of VRK1
for lysosomal degradation.
In conclusion, in this report we have identified and charac-
terized a possible autoregulatory loop between the tumor sup-
pressor p53 protein and its stabilizing protein, the VRK1 ki-
nase; this regulation, as an intermediate step, depends on the
p53 DNA-binding and transactivation domain and is not me-
diated by mdm2. This downregulation as final step requires the
transport of VRK1 from late endosomes to lysosomes and the
subsequent degradation mediated by lysosomal serine pro-
teases. The identification of this new regulatory circuit opens
up new possibilities to better understand the regulation of cell
proliferation in higher eukaryotes.
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